Cargando…
Pulmonary pharmacology /
Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthm...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
[Place of publication not identified] :
Academic Press,
2023.
|
| Colección: | Advances in pharmacology ;
volume 98 |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a22000007i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_on1392092334 | ||
| 003 | OCoLC | ||
| 005 | 20231120010750.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 230803s2023 xx o 000 0 eng d | ||
| 040 | |a OPELS |b eng |e rda |e pn |c OPELS |d EBLCP |d YDX |d OCLCQ |d UKMGB |d OCLCO | ||
| 015 | |a GBC3B1198 |2 bnb | ||
| 016 | 7 | |a 021089835 |2 Uk | |
| 019 | |a 1392341146 |a 1400792775 | ||
| 020 | |a 0443188815 |q (electronic bk.) | ||
| 020 | |a 9780443188817 |q (electronic bk.) | ||
| 020 | |z 9780443188800 | ||
| 020 | |z 0443188807 | ||
| 035 | |a (OCoLC)1392092334 |z (OCoLC)1392341146 |z (OCoLC)1400792775 | ||
| 050 | 4 | |a RM388 | |
| 082 | 0 | 4 | |a 615.72 |2 23/eng/20230803 |
| 245 | 0 | 0 | |a Pulmonary pharmacology / |c edited by W.S. Fred Wong. |
| 264 | 1 | |a [Place of publication not identified] : |b Academic Press, |c 2023. | |
| 300 | |a 1 online resource (312 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Advances in pharmacology ; |v volume 98 | |
| 520 | |a Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthma, COPD or pulmonary fibrosis, with perspective on the development of novel therapeutic strategies such as renin-angiotensin system modulators, mitochondrial function modulators, and non-antibacterial macrolides. Part of the volume is devoted to senotherapy for lung ageing in respiratory diseases, and novel pulmonary delivery technologies, including inhaled biologics. | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Intro -- Title page -- Table of Contents -- Advances in PHARMACOLOGY -- Copyright -- Contributors -- Preface -- Abbreviations -- Chapter One: Genomic and non-genomic effects of glucocorticoids in respiratory diseases -- Abstract -- Abbreviations -- 1 Introduction -- 2 Genomic mechanisms of action: GR activation -- 3 GR transactivation or transrepression-mediated mechanisms of action of GCs -- 4 Non-genomic mechanisms of action of GCs -- 5 Conclusion -- Acknowledgements -- References | |
| 505 | 8 | |a Chapter Two: Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment -- Abstract -- Abbreviation -- 1 Introduction -- 2 IL-5 -- 3 Mepolizumab -- 4 Reslizumab -- 5 Benralizumab -- 6 IL-4 and IL-13 -- 7 Dupilumab -- 8 Future developments -- 9 Conclusion -- Conflicts of interest -- References -- Chapter Three: Phosphodiesterase inhibitors and lung diseases -- Abstract -- Abbreviations -- 1 Introduction -- 2 Conclusion -- Conflict of interest statement -- References -- Chapter Four: Prospects for macrolide therapy of asthma and COPD | |
| 505 | 8 | |a Abstract -- Abbreviations -- 1 Introduction -- 2 Why asthma and COPD -- 3 What non-antimicrobial macrolide actions are relevant -- 4 Can antibiosis with macrolides be circumvented -- 5 Conclusion -- Acknowledgments -- References -- Note in proof -- Chapter Five: Targeting the renin angiotensin system for respiratory diseases -- Abstract -- Abbreviations -- 1 Introduction -- 2 Tareting renin angiotensin system in asthma -- 3 Targeting renin angiotensin system in COPD -- 4 Targeting renin angiotensin system in pulmonary fibrosis -- 5 Targeting renin angiotensin system in acute lung injury | |
| 505 | 8 | |a 6 Conclusion -- References -- Chapter Six: Progress in the development of kinase inhibitors for treating asthma and COPD -- Abstract -- Abbreviations -- 1 Introduction -- 2 Conclusion -- Conflict of interest statement -- References -- Chapter Seven: Anti-fibrotic strategies and pulmonary fibrosis -- Abstract -- Abbreviations -- 1 Introduction -- 2 IPF pathogenesis: Initiation of fibrogenesis -- 3 Pathways implicated in fibrosis -- 4 Growth factor and cytokine activation in IPF -- 5 Mechanotransduction and Hippo activation -- 6 Cellular players in IPF -- 7 IPF models -- 8 IPF drug treatment | |
| 505 | 8 | |a 9 Recommended drugs for IPF: Pirfenidone and nintedanib -- 10 Conclusion -- References -- Chapter Eight: Novel treatments against airway inflammation in COPD based on drug repurposing -- Abstract -- Abbreviations -- 1 Introduction -- 2 The novel pharmacologic targets -- 3 Conclusion -- Acknowledgements -- References -- Chapter Nine: Senotherapy for lung diseases -- Abstract -- Abbreviations -- 1 Introduction -- 2 Senotherapy for lung disease -- 3 Conclusion -- Conflict of interest -- References -- Chapter Ten: Delivery technology of inhaled therapy for asthma and COPD -- Abstract -- Abbreviations | |
| 650 | 0 | |a Pulmonary pharmacology. | |
| 650 | 6 | |a Pharmacologie pulmonaire. |0 (CaQQLa)201-0198800 | |
| 700 | 1 | |a Wong, W. S. Fred. | |
| 776 | 0 | 8 | |i Print version: |t PULMONARY PHARMACOLOGY. |d [Place of publication not identified] : ELSEVIER ACADEMIC PRESS, 2023 |z 0443188807 |w (OCoLC)1365043066 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/bookseries/10543589/98 |z Texto completo |